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Sarcoidosis is a multisystem   granulomatous disease   of unknown aetiology characterized by  
infiltration of non caseating granulomas in multiple organ systems. Sarcoidosis can have a 
plethora of cardiac manifestations which can mimic many other cardiovascular conditions ranging 
from asymptomatic electrocardiographic manifestations to life threatening arrhythmias resulting 
in sudden cardiac death. Even  more than a century after the first description of the disease by 
Norwegian dermatologist Caeser Boeck in 1899 [1], the aetiology of the disease remain elusive.
Pathophysiology  of sarcoidosis   
The pathological hallmark of sarcoidosis is the non caseating granuloma. The inciting event  
which  leads to the formation of the granuloma is still unknown. various environmental agents 
have been postulated as  triggers leading to granuloma formation including  propionibacter and 
mycobacterial infections, tree  pollen, photocopier toner dust, insecticides, vegetable dust and 
titanium eposure [2-4].                                                                                                     
Cardiac   involvement                                                                                      
Depending on the criteria used for diagnosis, cardiac involvement range from 5% to 50% [5,6]. 
The prognosis of cardiac sarcoidosis is consistently severe despite the variability in  prevalence 
and  clinical manifestations. It is the second most common cause of sarcoid related mortality after 
respiratory failure in western countries and probably most common cause of mortality in Japan 
[7,8].
Cardiac   manifestations                                                                                
Usual clinical manifestations of cardiac sarcoidosis (CS) include:                                    
1) Conduction abnormalities either symptomatic or asymptomatic. This include atrio ventricular 
or interventricular conduction abnormalities                                                                           
2) Ventricular arrhythmias                                                                                                   
3) Congestive heart failure                                                                                                   
4) Sudden cardiac death [5]                                                                                             
Conduction abnormalities are common. Both advanced AV block and ventricular arrhythmias can 
result in sudden cardiac death. Congestive heart failure has been observed in up to 30% cases [9-
11].  
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Apart from the common presentations, CS can mimic pericarditis, ARVD, and acute coronary 
syndromes  [12,13].                                                                                               
CHF is caused by myocardial infiltration of the sarcoid granulomas and   is typically rapidly 
progressive over weeks or months. Often there will be associated conduction abnormalities. 
Valvular regurgitation because of endocardial involvement also can contribute to development of 
congestive  heart failure.                                                                                          
Sudden cardiac death is the most dramatic and feared complication of  CS,  with an estimated 
incidence of 23 to 66% in different series [7,10,11].                                           
Diagnostic evaluations                                                                                             
Electrocardiography
Up to 75% cases of CS will demonstrate ECG abnormalities. Conduction abnormalities are most 
common, with a prevalence  ranging from 12% to 62%. Bundle branch blocks either complete or 
incomplete (12-61%) and atrioventricular block (23-60%) are common. Ventricular arrhythmias  
are common, and are described in up to 42% cases. Ventricular tachycardias are related to 
myocardial granulomas and subsequent fibrosis. Supraventricular arrhythmias are less common 
(0-15%). Atrial arrhythmias are more often due to atrial dilatation secondary to pulmonary 
involvement rather that atrial myocardial involvement [1]. Less common ECG abnormalities 
include sinus node dysfunction, repolarisation abnormalities, pseudo infarction Q waves, long QT 
or U waves.                                                                                                             
24 hour Holter                                                                                                   
Suzuki et al [14] have  reported a sensitivity of 67% and specificity of 80% in diagnosis of CS. 
More severe conduction disturbances than baseline, detection and characterization of  ventricular 
arrhythmias are the utilities of 24 hour Holter evaluation.                                         
Electrophysiological   study                                                                          
The role of programmed electrical stimulation in EP study  in CS is controversial [l1].  Studies 
have yielded conflicting results and were under powered to derive any meaningful conclusions 
[15,16]. Large prospective studies are needed before recommending the role of diagnostic EP 
studies in risk stratification of CS.                                                                                       
Echocardiography
Echocardiographic findings are variable in CS depending on the stage of the disease. It can be 
normal   in   early   stages   of   the   disease.   With   disease   progression,   14-56%   of   various 
echocardiographic manifestations are reported. There is no direct correlation of the ECG 
abnormalities with echocardiographic abnormalities.                                          
Regional wall motion abnormalities, segmental wall thickness abnormalities either thinning or 
thickening   especially of the basal interventricular septum, left ventricular aneurysms and in 
severe cases, dilatation of left ventricle with severe impairment of systolic function of the LV are 
reported in CS [9,10]. Mitral regurgitations either due to endocarditis or papillary muscle 
dysfunction is not uncommon. Small pericardial effusion is detected in up to 20% cases [17].
Tissue characterization and myocardial strain analysis using tissue Doppler imaging may also be 
valuable for diagnosis of CS [18,19]. These new imaging modalities need further evaluation and 
prospective studies before concluding on their utility in diagnosis in CS.                             
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Nuclear imaging                                                                                                                       
Myocardial perfusion scintigraphy   with single photon emission computed tomography (SPECT) 
and thallium 201(201Tl) or  technetium 99m (99mTc) have been used for evaluation of CS [1]. The 
characteristic phenomenon of reverse redistribution differentiates CS from coronary artery disease 
apart from the absence of   vascular territorial distribution   in the former. Resting perfusion 
typically show nonspecific segmental areas of decreased uptake  which will disappear or decrease 
in size during exercise or after administration of vasodilator agents like dipyridamole [20]. The 
exact mechanism of this phenomenon is not well elucidated, however most likely explanation is 
the presence of focal reversible micro vascular constriction in coronary arterioles surrounding 
sarcoid granulomas. Gated SPECT images will provide information about global LV function 
also.
Amount   of   reverse   redistribution   has   a   correlation   with   degree   of   improvement   under 
corticosteroids [21]. Conversely, isolated perfusion defects without clinical cardiac involvement is 
not associated with prognosis in CS [22,23].                                                                    
18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)                                         
FDG uptake in the myocardium typically show either a focal or focal on diffuse pattern (hot 
spots). These hot spots are presumably related to the sarcoid granulomas and inflammation.   
Small studies from Japan compared FDG-PET with  99m Tc-Sestamibi, Ga and 201Tl scintigraphy 
[24-27]. Overall sensitivity of FDG-PET is superior to other imaging modalites (85-100%). 
However specificity is slightly lower at 81.5 to 90.3%. There are no systematic prospective 
studies evaluating the role of FDG-PET in diagnosis  of CS or its superiority over the other 
nuclear imaging modalities to date.                                                                                       
Cardiac magnetic resonance imaging (CMR)                                                                                 
Contrast enhanced CMR is now considered to be the diagnostic investigation of choice in 
suspected CS. It can also be an aid for increasing the yield of endomyocardial biopsy. The CMR 
imaging appearance depends on the age of the pathological process. In acute granulomatous stage, 
sarcoid lesions will appear as  areas of high signal intensity on T1 and T2 weighted images 
[28,29] but can also appear as low intensity signal in T1 weighted images [30]. In the chronic 
stage of the disease, focal areas of myocardial thinning with contractile dysfunction  may result 
from scar formation. Myocardial scarring is typically patchy and will not confine to vascular 
territories. The sensitivity and specificity of CMR  are 100% and 78% respectively in a study 
conducted in 58 patients by Smedema et al [31]. CMR has probably a better specificity but a  
lower sensitivity that FDG-PET [15,32].                                                   
CMR can   detect pre clinical cardiac  involvement. A prospective study in 81 cases has 
demonstrated patients with myocardial involvement in CMR had an 11.5 fold higher  rate of 
deaths than those without myocardial involvement [31]. CMR also has prognostic implications 
with a positive correlation between the extent of myocardial involvement  as evidenced by late 
enhancement   with left ventricular dilatation,   ventricular   arrhythmias and impairment of LV 
function   [33-36].                                                                                              
Endomyocardial   biopsy                                                                                      
Because of the patchy nature of the disease, the sensitivity of biopsy is low even in patients with 
dilated cardiomyopathy. Endomyocardial biopsy will demonstrate noncaseting granulomas in less 
than 25% cases of CS [37,38].   It is not routinely done as a diagnostic work up for CS.
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Management
Once the diagnosis is made, risk stratification is done based on presence of LV function, ECG 
abnormalities, degree of granuloma  infiltration and some investigators argue for the role of EP 
studies to evaluate the risk of sudden cardiac death. Any of the abovementioned high risk markers 
are sufficient to initiate therapy in view of the progressive nature of the disease and risk of sudden 
arrhythmic   death.                                                                                                
Corticosteroids are the mainstay of drug therapy. There is no survival advantage for patients 
treated with  high   dose  steroids (> 30 mg ) compared with low dose (<30 mg) [39]. Severity of 
heart failure, LV end diastolic diameter, and presence of ventricular tachycardia are independent 
predictors for mortality from SHD. Early  initiation of steroid therapy before development of 
systolic dysfunction resulted in improved outcome.                                                                         
Other immunosuppressive therapies (azathioprine, cyclophosphamide, or hydroxy chloroquin) are 
used for patients who are intolerant to steroids or fail to respond to steroid therapy. Refractory 
cases may be treated with infliximab, a monoclonal antibody against TNF α. These agents have 
not been evaluated in any prospective randomized trials involving patients with SHD.         
Immunosuppression along with catheter ablation has been found useful in treating ventricular 
tachycardia storm in patients with CS [44].                                                                       
Management of  arrhythmias                                                                                 
The utility of anti arrhythmic drugs are not proven in CS  in any randomized trials. AAD may 
increase the risk of heart block, while amiodarone can cause pulmonary complications in the 
setting of already compromised respiratory function. In a case series of patients with sarcoidosis 
associated sustained ventricular tachycardia, anti arrhythmic drugs were associated with a high 
rate of recurrence of arrhythmia or sudden cardiac death or both. 4 of 7 cases where ICD was 
implanted received appropriate shocks [40]. ICD implantation should be considered in patients 
with  LV  dysfunction.                                                                                           
Utility of programmed ventricular stimulation in identifying high risk patients  is controversial. 
One study demonstrated an added value of EP study in identifying these patients with high risk of 
SCD. However there are no large prospective randomized studies available in this scenario.
Surgical therapies such as resection of ventricular aneurysm has been reported [41,42]. Cardiac 
transplantation is an option for patients with refractory heart failure or arrhythmias, however  
recurrence of disease in the allograft has been reported [43].                                         
Results from a multicentric registry demonstrated the efficacy of ablation in controlling the 
symptoms in CS. The disease process often involves a specific area in the basal right ventricle 
predisposing to peri tricuspid re entry. Both endocardial and epicardial ablatins were performed in 
these patients and peri tricuspid re entry VT could be eliminated in 70% of the cases [45]. 
Conclusions
CS is a great masquerader  which can mimic many cardiac conditions. Significant ventricular 
involvement is associated with high risk of arrhythmic death as well as heart failure. Diagnosis  
and risk stratification is a challenge and is aided by new diagnostic technologies like CMR and 
FDG PET studies. Immunosuppressant therapy  is the mainstay of treatment. Many  patients will 
need cardiac rhythm management devises mostly ICD. Ventricular tachycardia storm and ICD 
shocks will be a continuing problem for these cases. Electrophysiological studies and ablation of 
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the ventricular tachycardia has been shown promising in people with arrhythmia storm. Role of  
prophylactic substrate modificatin to avoid ICD shocks in these subset of patients is unknown and 
has to be evaluated in prospective clinical trials.                                             
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